Mindstate Design Labs

Mindstate Design Labs is pioneering a data-driven approach to psychedelic therapeutics by combining AI, pharmacology, and human experience reports. Its core asset is the Osmanthus platform, which analyzes vast datasets to identify how specific neurotransmitter receptor combinations produce distinct psychoactive states, guiding the design of novel compounds. The lead program, MSD-001, is in human studies and is designed to induce emotional and cognitive flexibility, with follow-on programs targeting other specific states. The company is led by a team with expertise in biotechnology investing, evolutionary biology, and CNS drug development, positioning it at the intersection of AI and next-generation mental health treatments.

Osmanthus: An AI-powered platform that synthesizes ~60,000 human psychoactive experience reports with biochemical data to map how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states, enabling the rational design of novel therapeutics.

Mindstate competes with well-funded psychedelics developers like Compass Pathways and Atai Life Sciences, who are advancing classic and novel compounds. Its key differentiation is the AI/ML-driven rational design of specific states, but it faces competition from larger pharmaceutical companies with deep CNS R&D capabilities that may enter the space.